Change over period: —
NSE · IPCALAB
IPCA LAB LTD
-7.7% from the 52-week high · +42.4% above the low
Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,167 full-time employees. The firm is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. The company offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The firm offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The firm has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
The short version. IPCA LAB LTD reported revenue of ₹2,910 crore for Sep 2026, up 13.8% from a year earlier. Net profit was ₹375 crore (up 32.5% year on year). Return on equity was 14.1% in Mar 2026. Promoter holding was 44.72% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
IPCA LAB LTD trades 7.7% below its 52-week high and 42.4% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹2,910 cr.
Sep 2026 net profit of ₹375 cr.
1.8 pts higher than a year earlier.
Revenue compounded at 15.5% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2910 | 2788 | 2388 | 2392 | 2556 | 2309 | 2247 | 2245 |
| Net profit | 375 | 402 | 299 | 326 | 283 | 233 | 68 | 248 |
| Net margin % | 12.9 | 14.4 | 12.5 | 13.6 | 11.1 | 10.1 | 3.0 | 11.1 |
| EPS (₹) | 14.79 | 15.84 | 11.79 | 12.86 | 11.14 | 9.19 | 2.67 | 9.78 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9646 | 8940 | 7705 | 6244 | 5830 | 5420 | 4649 | 3773 |
| Net profit | 1141 | 738 | 547 | 471 | 884 | 1140 | 606 | 445 |
| Net margin % | 11.8 | 8.3 | 7.1 | 7.5 | 15.2 | 21.0 | 13.0 | 11.8 |
| EPS (₹) | 44.98 | 29.08 | 21.57 | 18.58 | 34.85 | 44.93 | 23.99 | 17.6 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 14.1% in Mar 2026; debt to equity is 0.09.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 14.1 | 10.6 | 8.6 | 8.1 |
| Return on capital % | 16.4 | 13.0 | 11.2 | 11.6 |
| EBITDA margin % | 21.0 | 17.9 | 17.1 | 16.5 |
| Net margin % | 11.6 | 8.2 | 7.0 | 7.4 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 15.5% | 12.4% |
| Profit CAGR | 34.3% | 0.0% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 0.46 pts over 8 quarters.
Up 0.91 pts over 8 quarters.
+47 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.72 | 44.72 | 44.72 | 44.72 | 44.72 | 44.72 | 44.72 | 44.72 | 0.0 |
| FII | 11.07 | 10.76 | 10.67 | 10.43 | 10.63 | 10.63 | 10.73 | 11.53 | +0.46 |
| DII | 35.68 | 36.06 | 36.2 | 36.77 | 37.32 | 37.45 | 37.37 | 36.59 | +0.91 |
| Public | 8.53 | 8.46 | 8.41 | 8.07 | 7.33 | 7.2 | 7.18 | 7.15 | -1.38 |
Mutual fund holdings · Oct 2026
172 schemes hold this stock
125 the month before.
- DSP Healthcare Fund7.49% of NAV
- Baroda BNP Paribas Health and Wellness Fund6.06% of NAV
- quant Healthcare Fund5.37% of NAV
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND4.04% of NAV
- Motilal Oswal Nifty MidSmall Healthcare Index Fund4.03% of NAV
- Kotak Mid Cap Fund3.68% of NAV
- HDFC Mid Cap Fund3.47% of NAV
- Mirae Asset Healthcare Fund3.33% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for IPCA LAB LTD are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about IPCA LAB LTD
What is the IPCA LAB LTD share price?
IPCA LAB LTD (IPCALAB) last closed at ₹1,860.50, up 0.35% on the day. Its 52-week range is ₹1,302.00 to ₹2,009.60.
What is the market cap of IPCA LAB LTD?
IPCA LAB LTD has a market capitalisation of about ₹47,042 crore. Its price-to-earnings ratio is 33.6.
How are IPCA LAB LTD's latest results?
IPCA LAB LTD reported revenue of ₹2,910 crore for Sep 2026, up 13.8% from a year earlier. Net profit was ₹375 crore (up 32.5% year on year). Return on equity was 14.1% in Mar 2026. Promoter holding was 44.72% in Sep 2026, up 0.00 points over 8 quarters.
Who owns IPCA LAB LTD?
As of Sep 2026, shareholding was: Promoter 44.72%, FII 11.53%, DII 36.59%, Public 7.15%.
How many mutual funds hold IPCA LAB LTD?
172 mutual fund schemes held IPCA LAB LTD in October 2026. That compares with 125 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 05 Aug 2025 · Final Dividend - Rs. 2
- 27 Nov 2024 · Interim Dividend - Rs. 2
- 06 Aug 2024 · Final Dividend - Rs. 2
- 22 Nov 2023 · Interim Dividend - Rs. 2
- 22 Nov 2022 · Interim Dividend - Rs. 4
- 10 Jan 2022 · Stock Split From Rs.2/- to Rs.1/-
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.